Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
16.26
+0.09 (0.56%)
Oct 6, 2025, 2:48 PM EDT - Market open
Roivant Sciences Employees
Roivant Sciences had 750 employees as of March 31, 2025. The number of employees decreased by 158 or -17.40% compared to the previous year.
Employees
750
Change (1Y)
-158
Growth (1Y)
-17.40%
Revenue / Employee
$30,977
Profits / Employee
-$654,177
Market Cap
11.10B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 750 | -158 | -17.40% |
Mar 31, 2024 | 908 | 4 | 0.44% |
Mar 31, 2023 | 904 | 41 | 4.75% |
Mar 31, 2022 | 863 | 198 | 29.77% |
Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ROIV News
- 11 days ago - Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 13 days ago - Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Roivant Sciences Ltd. - Special Call - Seeking Alpha
- 19 days ago - Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial - Benzinga
- 19 days ago - Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial - Reuters
- 19 days ago - Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) - GlobeNewsWire
- 24 days ago - Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List - GlobeNewsWire